EX-99.2 3 d277667dex992.htm EX-99.2 EX-99.2

PRODUCT SALES STATEMENT, FOR THE PRODUCT SALES MEASURING PERIOD ENDED SEPTEMBER 30, 2016

As called for under §5.4 of the Contingent Value Rights Agreement (the “CVRA”) by and between Sanofi (formerly known as sanofi-aventis) and American Stock Transfer & Trust Company LLC dated as of March 30, 2011. On May 13, 2016, American Stock Transfer & Trust Company, LLC (“AST”) tendered its resignation as trustee under the CVRA to Sanofi. As of June 30, 2016, UMB Bank, National Association has replaced AST and will serve as Successor Trustee under the CVRA. All capitalized terms used in the present Product Sales Statement have the respective meanings ascribed to them in the CVRA. Amounts set forth herein are not necessarily indicative of results that will be achieved in subsequent Product Sales Measuring Periods.

Sales data to be provided prior to fulfilment of Product Sales Milestone #1:

For the Product

 

Market

   Q3 2016     Q2 2016     Q1 2016     Q4 2015  
    (I)     (II)     X - rate     (I)     (II)     X - rate     (I)     (II)     X - rate     (I)     (II)     X - rate  

Major Markets

                        

USA

     85,1 (4)      71,6        1,0        75.9 (4)      63.2        1.000        61.1 (4)      50.5        1.000        55.6        48.1        1.000   

UK

     16,5 (3)      15,2        0,7611        14.9 (3)      13.7        0.6968        13.2 (3)      12.2        0.6989        10.4 (3)      9.3        0.6592   

France

                        

Germany

     11,7 (2)      10,8        0,8959        14.7 (2)      13.6        0.8855        12.9 (2)      12.1        0.9076        12.6 (2)      12.0        0.9133   

Italy

     3,3 (6)      2,3        0,8959        4.1        2.9        0.8855        2.9        2.0        0.9076        2.1        1.2        0.9133   

Spain

     4,6 (5)      3,1        0,8959        6.9 (5)      4.0        0.8855        5.1        2.9        0.9076        2.8        1.3        0.9133   

Subtotal

     121,2        102,9          116.5        97.4          95.2        79.7          83.5        71.9     

All other

     30,3        21,9        Misc.        32.2        24.1        Misc.        20.1        17.8        Misc.        20.6        16.4        Misc.   

Exclusions

                        

Oncology(1)

     0.1        0.1          0.1        0.1          0.1        0.1          0.1        0.1     

Transplant

Indications*

       **        **          **        **          **        **          **        **   

Legend:

 

(I): Aggregate gross amount invoiced by the Company, its Affiliates and its licensees for sales of the Product by the Company, its Affiliates and licensees of the Company and its Affiliates to third parties, in millions of United States dollars.
(II): Product Sales, in millions of United States dollars.
X-rate: Exchange rates used for conversion of the specified Major Market’s foreign currency into United States dollars for the quarter indicated. Exchange rates for other markets will be provided to the extent there are sales invoiced in currencies other than the United States dollar.
*: Note that amounts appearing in this line are a subset of the amounts appearing in the “Oncology” line, above, provided for information purposes and calculated by reference to relevant data compiled by the UNOS (United Network for Organ Sharing).
**: During the period under review, there were no Transplant Indication stock keeping units (SKUs) recorded. UNOS data specifying Transplant Indication usage for the specified period is not avail able as of the date of this Statement.
N/A: Not applicable.
(1): Commercialized Campath® is currently available exclusively in Japan, for the rest of world Campath® is being made available to patients at no cost through a patient access/distribution program. Commercial sales in Japan amount to 0.1 million of United States dollars during the quarter.
(2) Major Market Product Sales with respect to Germany were sales for the period from January 1, 2014 to December 31, 2014. Sales in subsequent periods are not used to calculate Product Sales Milestone #1.
(3) Major Market Product Sales with respect to UK were sales for the period from October 1, 2014 to September 30, 2015. Sales in subsequent periods are not used to calculate Product Sales Milestone #1.
(4) Major Market Product Sales with respect to USA were sales for the period from January 1, 2015 to December 31, 2015. Sales in subsequent periods are not used to calculate Product Sales Milestone #1.
(5) Major Market Product Sales with respect to Spain were sales for the period from April 1, 2015 to March 31, 2016. Sales in subsequent periods are not used to calculate Product Sales Milestone #1.
(6) Major Market Product Sales with respect to Italy were sales for the period from July1, 2015 to June 30, 2016. Sales in subsequent periods are not used to calculate Product Sales Milestone #1.

Do Product Sales in the Product Sales Measuring Period ended September 30, 2016 include Product Sales of a Combination Product?    ☒  No    ☐  Yes

Has any Product Sales Milestone been achieved during the Product Sales Measuring Period ended September 30, 2016?    ☒  No    ☐  Yes

After due inquiry and to the best of the knowledge and belief of the undersigned, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

 

Sanofi
By:  

/s/ Jérôme Contamine

Name:   Jérôme Contamine
Title:   Executive Vice President, Chief Financial Officer
Date: October 27, 2016